Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 -1.88%74 EV-to-FCF is 67.89 as of Jul. 15, 2026, which is 379% above its 10-year median of 14.16. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Diva Laboratories ranks worse than 81.82% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Diva Laboratories's Enterprise Value is NT$1,342.2 Mil.
Diva Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$19.8 Mil. Therefore, Diva Laboratories's EV-to-FCF for today is 67.89.
The historical rank and industry rank for Diva Laboratories's EV-to-FCF or its related term are showing as below:
ROCO:4153'
s EV-to-FCF Range Over the Past 10 Years
Min: -177.83 Med: 14.16 Max: 1295.99
Current: 67.89
During the past 13 years, the highest EV-to-FCF of Diva Laboratories was 1295.99. The lowest was -177.83. And the median was 14.16.
ROCO:4153's EV-to-FCF is ranked worse than 81.82% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.47
vs ROCO:4153: 67.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diva Laboratories's PE Ratio (TTM) for today is calculated as:
Diva Laboratories's share price for today is NT$31.25.
Diva Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diva Laboratories EV-to-FCF Related Terms
Diva Laboratories EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diva Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's EV-to-FCF falls into.
Diva Laboratories's current Enterprise Value is NT$1,342.2 Mil.
Diva Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$19.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories (ROCO:4153) has a EV-to-FCF of 67.89 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diva Laboratories and its competitors. This is 379% above median its historical median of 14.16. According to the industry distribution chart, Diva Laboratories ranks #81 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 81.8%.
Is Diva Laboratories' EV-to-FCF too high?
Diva Laboratories' current EV-to-FCF of 67.89 is 379% above median its 10-year median of 14.16. The Medical Diagnostics & Research industry median EV-to-FCF is 25.47. Diva Laboratories' value of 67.89 is 166.5% above this industry median. Based on the distribution chart, Diva Laboratories ranks #81 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #81 out of 99 companies for EV-to-FCF. This places Diva Laboratories in the lower half of its industry. The industry median EV-to-FCF is 25.47. Diva Laboratories' value of 67.89 is 166.5% above this benchmark. While the company's 10-year median is 14.16 vs. the industry median of 25.47, Diva Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.47, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current EV-to-FCF of 67.89 is 166.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current EV-to-FCF is 67.89, which is 379% above median its own 10-year median of 14.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.25 — trading 17.8% below its estimated fair value. The current EV-to-FCF is 67.89, which is 379% above median its 10-year median of 14.16 and 166.5% above the Medical Diagnostics & Research industry median of 25.47. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current EV-to-FCF is 67.89 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.25 is trading 17.8% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
EV-to-FCF: 67.89 (379% above median its 10-year median of 14.16)
GF Value™: NT$38.03 vs. price of NT$31.25 (17.8% below fair value)
Industry Position: 166.5% above the Medical Diagnostics & Research median (#81 of 99)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
